KLF8 is associated with poor prognosis and regulates glycolysis by targeting GLUT4 in gastric cancer. Issue 8 (24th May 2019)

• Record Type: Journal Article
• Authors: Mao, Anwei; Zhou, Xiang; Liu, Yanxia; Ding, Junbin; Miao, Aiyu; Pan, Gaofeng
• Is Part Of: Journal of cellular and molecular medicine. Volume 23:Issue 8(2019)
• Page Start: 5087
• Page End: 5097
• Publication Date: 2019-05-24
• Subjects: gastric cancer -- KLF8 -- prognosis -- Warburg effect; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.14378
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Krüppel‐like transcription factor (KLF) family is involved in tumorigenesis in different types of cancer. However, the importance of KLF family in gastric cancer is unclear. Here, we examined KLF gene expression in five paired liver metastases and primary gastric cancer tissues by RT‐PCR, and immunohistochemistry was used to study KLF8 expression in 206 gastric cancer samples. The impact of KLF8 expression on glycolysis, an altered energy metabolism that characterizes cancer cells, was evaluated. KLF8 showed the highest up‐regulation in liver metastases compared with primary tumours among all KLF members. Higher KLF8 expression associated with larger tumour size ( P < 0.001), advanced T stage ( P = 0.003) and N stage ( P < 0.001). High KLF8 expression implied shorter survival outcome in both TCGA and validation cohort ( P < 0.05). Silencing KLF8 expression impaired the glycolysis rate of gastric cancer cells in vitro. Moreover, high KLF8 expression positively associated with SUVmax in patient samples. KLF8 activated the GLUT4 promoter activity in a dose‐dependent manner ( P < 0.05). Importantly, KLF8 and GLUT4 showed consistent expression patterns in gastric cancer tissues. These findings suggest that KLF8 modulates glycolysis by targeting GLUT4 and could serve as a novel biomarker for survival and potential therapeutic target in gastric cancer.